All News

Found 8,290 articles

• Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

  4/4/2024

  Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will share new data at the 20th European Association of Dermato-Oncology Congress, being held April 4-6, 2024, in Paris, France, that demonstrate the ability of its DecisionDx-Melanoma and DecisionDx-SCC tests to improve clinical-decision making through precise risk-stratification of patients with cutaneous melanoma and squamous cell carcinoma.

• American Skin Association Announces New Board Member Joseph F. Merola, MD, MMSc, FAAD, FACR

  4/4/2024

  American Skin Association announced that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.

• Paragon Therapeutics Announces Oruka Therapeutics Has Entered into Merger Agreement with ARCA biopharma to Advance Novel Treatments for Chronic Skin Diseases

  4/3/2024

  Paragon Therapeutics announced today that the third company founded based on assets generated by Paragon, Oruka Therapeutics ("Oruka"), has entered into a definitive agreement with ARCA biopharma to combine the companies in an all-stock transaction.

• Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency

  4/3/2024

  Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company) announced today that it has received agreement from the European Medicines Agency (EMA) on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) patients with early-stage disease.

• Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

  4/3/2024

  Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced submission of an investigational new drug application to the U.S. Food and Drug Administration for the treatment of metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis, for the Company’s ongoing Phase IIb clinical study.

• Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

  4/2/2024

  Roivant and Priovant Therapeutics announced positive results from the Phase 2 study evaluating brepocitinib in non-anterior non-infectious uveitis, showing the strongest efficacy data in NIU observed to date.

• Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

  4/2/2024

  Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that the Company’s executive management is scheduled to present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 12:45 p.m. Eastern time.

• Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

  4/2/2024

  Cantargia Cantargia reported publication of promising preclinical data supporting the potential of the anti-IL1RAP antibody CAN10 as treatment of atherosclerosis.

• Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

  4/1/2024

  Sol-Gel Technologies, Ltd. announced that Padagis Israel Pharmaceuticals Ltd, Sol-Gel’s collaboration partner, submitted a first-to-file Abbreviated New Drug Application to the U.S. Food and Drug Administration for Roflumilast Cream, 0.3%, a drug product generic to Zoryve® Cream, indicated for the treatment of plaque psoriasis in patients six years of age and older.

• Analyses Find Patients With Polycythemia Vera (PV) Treated With BESREMi® (ropeginterferon alfa-2b) Had Increased Probability of Achieving Complete Hematologic Response

  4/1/2024

  PharmaEssentia USA Corporation, a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the publication of an original article in the British Journal of Clinical Pharmacology, “Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.”

• Can-Fite Reports 2023 Financial Results and Clinical Update

  3/28/2024

  Can-Fite BioPharma Ltd. announced financial results and clinical updates for the twelve months ended December 31, 2023.

• Dermatology Devices Market Size, CAGR, Trends and Forecast 2024 to 2033

  3/28/2024

  According to Vision Research Reports, the global dermatology devices market size was estimated at USD 15.31 billion in 2023

• China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs

  3/28/2024

  On March 27, 2024, China Medical System released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines were directly sold by the Group, the turnover would be RMB 9,472 million, a year-on-year decrease of 9.8%.

• Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

  3/28/2024

  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8-11, 2024.

• Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

  3/28/2024

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at the 2024 Schizophrenia International Research Society (SIRS) Annual Meeting, to be held April 3-7, 2024, in Florence, Italy.

• InnoCare Releases 2023 Results and Business Highlights

  3/28/2024

  InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

• AMPEL BioSolutions' Lupus Test Launches to Predict Flares & Drug Targets

  3/27/2024

  AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus.

• Castle Biosciences Announces Updates to its Board of Directors

  3/27/2024

  Castle Biosciences, Inc. announced that Rodney Cotton has been appointed to its board of directors, effective immediately, and will stand for election at Castle’s 2024 Annual Meeting of Stockholders, expected to be held in May 2024.

• STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings

  3/27/2024

  STRATA Skin Sciences, Inc. announced financial results for the fourth quarter and full-year ended December 31, 2023.

• Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders

  3/27/2024

  ASLAN Pharmaceutical (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give a virtual company presentation at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders, to be held virtually on Thursday, March 28, 2024.